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Abstract
Background: Due to potential proarrhythmic side-ef-
fects levo-α-Acetylmethadol (LAAM) is currently not
available in EU countries as maintenance drug in the
treatment of opiate addiction. However, recent studies
and meta-analyses underline the clinical advantages of
LAAM with respect to the reduction of heroin use.
Thus a reappraisal of LAAM has been demanded. The
aim of the present study was to evaluate the relative
impact of LAAM on QTc-interval, as a measure of
pro-arrhythmic risk, in comparison to methadone, the
current standard in substitution therapy.
Methods: ECG recordings were analysed within a ran-
domized, controlled clinical trial evaluating the effica-
cy and tolerability of maintenance treatment with
LAAM compared with racemic methadone. Record-
ings were done at two points: 1) during a run-in period
with all patients on methadone and 2) 24 weeks after
randomisation into methadone or LAAM treatment
group. These ECG recordings were analysed with re-
spect to QTc-values and QTc-dispersion. Mean values
as well as individual changes compared to baseline pa-
rameters were evaluated. QTc-intervals were classified
according to CPMP-guidelines.
Results: Complete ECG data sets could be obtained in
53 patients (31 LAAM-group, 22 methadone-group).
No clinical cardiac complications were observed in ei-
ther group. After 24 weeks, patients receiving LAAM
showed a significant increase in QTc-interval (0.409s
ﾱ 0.022s versus 0.418s ﾱ 0.028s, p = 0.046), whereas
no significant changes could be observed in patients
remaining on methadone. There was no statistically
significant change in QTc-dispersion in either group.
More patients with borderline prolonged and pro-
longed QTc-intervals were observed in the LAAM
than inthemethadonetreatmentgroup(n = 7 vs. n=1;
p = 0.1).
Conclusions: In this controlled trial LAAM induced
QTc-prolongation in a higher degree than methadone.
Given reports of severe arrhythmic events, careful
ECG-monitoring is recommended under LAAM med-
ication.
Key words: LAAM, methadone, opiate addiction, car-
diac arrhythmia, QTc-interval
INTRODUCTION
The synthetic opioid levo-α-acetylmethadol (LAAM)
is a long-acting full ﾵ-opioid agonist which was ap-
proved by the U.S. Food and Drug Administration
(FDA) for maintenance treatment of opioid depen-
dence in 1993. There are many studies comparing the
efficacy and safety of LAAM with methadone as med-
ication in maintenance treatment for heroin addiction
[1-4]. In clinical trials, LAAM was found to be compa-
rable to methadone with respect to reduction of illicit
opiate use, treatment retention, employment, clinic at-
tendance, and involvement in illegal activities [5]. The
safety of LAAM in long-term treatment was similar to
that of methadone in a meta-analysis [6].
Reports of cases of life-threatening ventricular ar-
rhythmias (especially torsade de pointes) have raised
concerns about potential arrhythmogenic effects both
of LAAM [7, 8] and methadone [9, 10]. Both LAAM
and methadone belong to a group of drugs that block
cardiac potassium channels responsible for mediating
ventricular repolarisation [11]. In the context of these
cardiac side effects, the European Medicines Agency
(EMEA) recommended the suspension of the market-
ing authorization for LAAM in 2001 and the United
States Food and Drug Administration (FDA) required
the addition of a “black box” warning on the LAAM
label [12]. However, a recent study showing higher ef-
ficiency of LAAM with respect to suppression of
heroin use revived the discussion whether potential
risks for cardiac arrhythmias really outweigh the ad-
vantages of LAAM [13, 14].
In clinical practice, the prolongation of the QT-in-
terval (time interval including myocardial de- and re-
polarisation) is a surrogate marker for the risk of de-
veloping torsades de pointes tachycardia (TdP) [15].
Little is known regarding the extent of LAAM-in-
duced QT-prolongation and the relative risk of LAAM
compared with racemic methadone for the occurrence
of QT-prolongation. Therefore the aim of the present
study was to analyse corrected QT-duration and QT-
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METHODS
SUBJECTS
ECG recordings were obtained from participants in a
phase III clinical trial [16]. Heroin addicts on metha-
done maintenance treatment for at least one month
with a stable methadone dosage for at least two weeks
were eligible for the study. Inclusion criteria were age
between 18 to 65, diagnosis of opioid dependence,
daily methadone dose less than 100 mg methadone
hydrochloride, negative urine drug screen for opiates
during the screening period, negative pregnancy test
and absence of significant other psychiatric or somat-
ic illness. Subjects with known cardiac disease were
excluded. The trial was endorsed and supervised by
the Bundesinstitut f￼r Arzneimittel und Medizinpro-
dukte (German Federal Institute for Drugs and Med-
ical Devices, Project Nr. 430 48 20) and approved by
all local ethics committees. All patients provided writ-
ten informed consent to their participation in the
study.
STUDY DESIGN
The parent study was designed as an open, multi-cen-
tre, flexible dose, parallel-group, randomised trial [16].
The study consisted of two parts: the run-in period
and the treatment phase (Fig. 1). During the run-in
phase, all patients received standardised treatment
with racemic methadone solution. At the end of the
run-in phase, patients were randomly allocated to one
of two treatment groups in a 1:1 ratio: LAAM dis-
persible tablets 3 times/week (treatment group I) or
racemic methadone solution daily (treatment group
II). The maximum dosage was 100 mg/day of metha-
done or 130 mg LAAM on Mondays and Wednesdays
and 160 mg on Fridays (1.3 and 1.6 times the daily
methadone dose).
During the treatment period (weeks 1 to 24), outpa-
tient visits were performed every week. The individual
endpoint assessment of all efficacy and safety parame-
ters including an ECG recording was carried out after
regular completion (week 24) or premature discontinu-
ation of the study (Fig. 1).
URINE TESTING
Urine drug-screening was carried out randomly two
times per week. To minimise the risks of manipulation
of the urine sample, the fresh urine was checked on
temperature using the Franklin collector [17].
ECG-RECORDINGS
Surface resting ECG recordings were performed in a
standard 12-lead manner at the beginning of the run-
in period and in week 24 of the treatment period in all
participating centres. The "week 24" ECG-recording
was performed at the individual end of study, which
could be after 24 weeks of randomised treatment or at
the time of early discontinuation.
DATA ANALYSIS
Each ECG-recording was analysed in accordance with
the CPMP-guidelines [18]. ECG-analysis was blinded
for the assigned treatment groups. The following para-
meters were determined.
QTc-interval: The QT-interval was measured in three
consecutive beats in lead Einthoven II, and the arith-
metic mean of these values was calculated [19]. The
corrected QT-interval (QTc-interval) was then calcu-
lated using Bazett’s-formula (QTc = QT/SQR RR)
[20, 21].
QTc-dispersion (QTD): QTD is defined as the differ-
ence between the maximum and minimum QTc-inter-
val in a 12 lead electrocardiogram. QTD values were
calculated as the arithmetic mean over the three con-
sidered complexes [22].
CPMP-CLASSIFICATION
According to the CPMP-guidelines the following clas-
sifications are used.
QTc-interval values:
Adult Males Adult Females
Normal ≤430 ms ≤450 ms
Borderline 431-450 ms 451-470 ms
Prolonged >450 ms >470 ms
CHANGES OF QTC-INTERVAL UNDER MEDICATION
Difference <30 ms: Unlikely to raise significant
concerns about the potential risk of a drug induced
arrhythmia including TdP (increased risk unlikely).
Difference 30-60 ms: More likely to represent a drug
effect, raising concern about the potential risk of a
drug to induce arrhythmias including TdP (increased
risk possible).
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Fig. 1. Study design. ECG recordings were done
at the beginning of the run-in period and at the
end of the treatment period.
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risk of a drug to induce arrhythmias including TdP
(increased risk probable).
QTC-DISPERSION
An increased risk of arrhythmia is assumed when the
absolute QTc-dispersion is > 100 ms or the change in
QTc-dispersion is > 100%.
STATISTICAL ANALYSIS
Data are given as means ﾱ standard deviation. Contin-
uous variables were compared before and during treat-
ment using t-test for dependent samples. Differences
between treatment groups with regard to the incidence
of classes according to CPMP-classification were
analysed using chi-square statistics. P-values <0.05
were considered statistically significant. Data analysis
was performed with the SPSS (Version 8.0).
RESULTS
84 patients were initially enrolled into the clinical trial.
Only patients with complete ECG data sets were in-
cluded in the data analysis. Complete data sets of two
ECGs could be obtained for 53 patients (31 LAAM-
group, 22 methadone-group). The average dosages of
methadone or LAAM were comparable in both groups
in the run-in and in the treatment phase. For patient
characteristics see Table 1.
No faints, syncopes or other clinical signs of car-
diac disease were observed either in the LAAM group
or in the methadone group. Urine drug screening re-
vealed continuous use of cocaine during the study in
one patient with abnormal QTc intervals. Another pa-
tient with that abnormality received a tricyclic antide-
pressant. Both patients were in the LAAM group and
had normal QTc intervals while receiving methadone
in the run-in phase.
ECG - PARAMETRIC ANALYSIS
Mean QTc-interval before starting study medication
was 0.409 s ﾱ 0.022 s in the LAAM group and 0.406 s
ﾱ 0.029 s in the methadone group, respectively. There
were no significant differences between both groups.
A significant increase in QTc-interval in the LAAM
group was observed after 24 weeks or at the endpoint
of individual study treatment, respectively (0.409s ﾱ
0.022s at run-in versus 0.418s ﾱ 0.028s at 24 weeks, p
= 0.046). In contrast, no significant change occurred
in the methadone group (0.406 s ﾱ 0.029 s at run-in
versus 0.405 s ﾱ 0.025 s at 24 weeks) (Fig. 2).
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Table 1. Patient characteristics in both study groups and average dosages during run-in phase and treatment phase in both
groups.
Treatment Group Methadone LAAM
(METH)
Total number (n) 22 31
Gender 12 F / 10 M 11 F / 20 M
Age (avg) 31.0 yrs 27.9 yrs
Average dosage during run-in period 72.0 ﾱ 25.5 mg daily 73.5 ﾱ 25.7 mg daily
(METH in both groups)
Average dosage during treatment phase 69 ﾱ 27.6 mg METH Mon & Wed Fri
89.6 ﾱ 32.4 mg LAAM 109.7 ﾱ 39.5 mg LAAM
equiv. to 68.9 ﾱ 24.9 mg equiv. to 68.6 ﾱ 24.7 mg
METH* METH*
*For better comparability, METH equivalents are shown in the LAAM groups assuming a factor of 1.3 (Monday & Wednesday)
and 1.6 (Friday).
Fig. 2. Comparison of QTc intervals between run-
in and treatment phase separately analysed for the
methadone- and LAAM-group. Mean ﾱ SD.
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0.040 s ﾱ 0.013 s in the LAAM group and 0.046 s ﾱ
0.015 s in the methadone group. There were no signif-
icant differences between both groups. There was a
non-significant increase in QT-dispersion in the
LAAM group (0.045 ﾱ 0.016 s; p = 0.19) at 24 weeks
and a non-significant decrease in the methadone
group at 24 weeks (0.042 s ﾱ 0.011 s) (Fig. 3).
ECG - NON-PARAMETRIC ANALYSIS
Patients were classified according to the CPMP-classi-
fication. Before randomisation in the LAAM-group, 2
patients had borderline QTc-intervals and 1 patient
had prolonged QTc-intervals. After 24 weeks of med-
ication with LAAM, 4 patients showed borderline
QTc-intervals and 3 patients showed prolonged QTc-
intervals. Therefore, when considering both borderline
and prolonged QTc-intervals as abnormal, 3 patients
showed abnormal QTc-intervals before randomisation
and 7 patients showed abnormal QTc-intervals after
24 weeks of LAAM treatment. In the methadone
group 1 patient showed borderline prolonged QTc-in-
tervals and 1 patient showed prolonged QTc-intervals
before randomisation. After 24 weeks of methadone
treatment 1 case of borderline prolongation and no
case of prolonged QTc-intervals could be observed.
Taking borderline and prolonged QTc-intervals to-
gether more patients with QTc-prolongation were ob-
served in the LAAM treatment group than in the
methadone treatment group (n = 7 vs. n = 1), however
this did not reach statistical significance (p = 0.1). Ac-
cording to the CPMP-guidelines, 2 patients in the
LAAM group showed an increase in QTc-interval be-
tween 30 and 60 ms and 2 patients > 60 ms after a
treatment period of 24 weeks or at the endpoint of in-
dividual study treatment, respectively. In the
methadone group 1 patient showed an increase in
QTc-interval between 30 und 60 ms. The difference
between both groups was not significant.
DISCUSSION
Methadone, introduced in the late 1960s, and LAAM,
approved in 1993 by the FDA as maintenance drug,
are two full ﾵ-opioid agonists. Clinical studies suggest
that LAAM is at least as efficient for substitution
treatment as methadone. In addition, LAAM provides
the option of less-than-daily doses which is made pos-
sible by the long half-lives of its two active metabo-
lites. However, reports on potential proarrhythmic
side-effects of LAAM raised concerns about its role as
therapy for opiate dependence. Thus the European
Medicines Agency (EMEA) recommended to suspend
the marketing authorization for LAAM in 2001, and
the United States Food and Drug Administration
(FDA) required the addition of a “black box” warning
on the LAAM label.
Prompted by recent reports on potential advantages
of LAAM with respect to promoting reduction of opi-
ate use, the need of a re-evaluation of LAAM has been
demanded [13, 24, 25]. Thus the aim of the present
study was to compare specific ECG changes in patients
on LAAM and methadone substitution, the current
standard in opioid substitution. The main finding of
the present randomized study in opioid addicts is that
switching from methadone to LAAM treatment in-
creases the mean QTc-interval and the number of indi-
vidual patients with abnormal QTc-interval compared
with patients continuously on racemic methadone.
To our knowledge there is only one randomized
study by Wedam et al. [26] examining the effect of
methadone, LAAM and buprenorphine on QT-inter-
vals. They found that the incidence of prolonged QTc-
intervals were considerable higher with LAAM and
methadone than with buprenorphine. LAAM showed a
tendency towards enhanced absolute QTc-values and
an increase under medication as compared to metha-
done, what is in concordance with our findings.
There are several studies investigating QTc-prolon-
gation and cardiac arrhythmia in patients on methadone
[9, 10, 27, 28]. Generally, QTc-interval is increased as
compared with patients taking heroin [29] or with a ref-
erence group with the same age and sex [30]. Clinical
complications and arrhythmias under methadone med-
ication have predominantly been observed under high
dosages (markedly more than 100 mg per day) [28],
whereas mean daily methadone dosage was 69 mg in
our study. As in the present study patients were on
methadone during the run-in period, the rise in QTc-in-
tervals and the increase of patients with prolonged
QTc-intervals under LAAM medication might point to
a higher pro-arrhythmic impact of LAAM when taking
QTc-interval as a surrogate marker for arrhythmic risk.
In several clinical and epidemiological studies the re-
liability of the QT-interval measurements in the lead
Einthoven II has been validated [31]. A prolongation of
the QTc-interval is associated with an increased risk of
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Fig. 3. Comparison of QT-dispersion between
run-in and treatment phase separately analysed for
the methadone- and LAAM-group. Mean ﾱ SD.
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tients with prior cardiovascular disease [32]. However, a
direct cause-effect relation between a prolonged QTc-
interval and the occurrence of ventricular arrhythmias
has not been established [33]. In addition to the drug
induced change of mean values of QTc-intervals in a
population, the effect of the drug on QTc-intervals in
individual patients has to be assessed. The evaluation of
individual cases is of special interest as there is a partic-
ular predisposition for the occurrence of torsades de
pointes tachycardias in certain individuals [34]. On the
basis of observational studies it has been speculated
that ion channel single nucleotide polymorphisms
(SNPs) may be partially responsible for this susceptibil-
ity [35]. Thus if a patient develops a marked prolonga-
tion of the QTc-interval, this must be considered as a
significant and potentially serious drug effect which
might be more important than a slight increase in mean
values described in a sample of patients [36].
Given our results and the literature, there should be
a careful weighing up of the pros and cons regarding
the availability of LAAM as maintenance drug in the
EU. On the one hand, LAAM is a maintenance drug
of proven efficacy and with some advantages com-
pared to methadone. On the other hand, there is an in-
creased risk of cardiac complications. We agree with
Stimmel [37] that the known cardiac risk should lead
to the improvement of cardiac monitoring, but not to
a principal withdrawal of LAAM from the market.
Known risk factors for cardiac side effects under
LAAM are previous cardiovascular disease, excess dos-
es of LAAM, medication inhibiting the P450-3A4 sys-
tem, and medication lowering serum potassium or
magnesium. Taking these factors into account, Stim-
mel [37] recommended a baseline ECG in all patients
prior to LAAM treatment with a subsequent exclusion
of patients with prolonged QTc-interval. Additional
ECGs should be performed two weeks after onset of
LAAM treatment and after every substantial change of
dosage. Eventually, in individual cases there might be
the dilemma between the risk of continuous heroin
use and the risk of cardiac complications under
methadone or LAAM treatment [38].
LIMITATION
84 subjects were initially enrolled in the study and 53
complete ECG data sets could be obtained. This dis-
crepancy was due to lack of compliance with study
procedures, e.g. drop-out from study treatment. It re-
flects the difficulties in conducting clinical studies in
this patient group and has also been reported from
other studies [39].
QTc-intervals and QT-dispersion represents only
surrogate markers for an increased risk for arrhyth-
mias. The present study is not powered to evaluate
hard endpoints as sudden cardiac death. Notwith-
standing QTc-interval is the best surrogate marker for
TdP at the moment.
CONCLUSION
In the present study we could show that an indicator
for an increased risk for cardiac arrhythmia was signif-
icantly more pronounced in patients after switching
from methadone to LAAM compared with patients re-
maining on methadone. This suggests that LAAM
might have a higher potential to induce cardiac ar-
rhythmias than does methadone in comparable
dosages, however, no clinical cardiac symptoms were
reported in either group. In sum, in patients with
known cardiac risk factors, methadone might be
preferable to LAAM, but the statement of Jaffe [14]
should be seriously considered that it would be benefi-
cial for opiate addicted patients if LAAM were avail-
able as a maintenance drug.
Statement of Interest: The study was supported by Hexal
(Germany).
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